Abstract: A set of primers and probes for simultaneous detection of Cymbidium mosaic virus (CymMV), Odontoglossum ringspot virus (ORSV), and Cymbidium ringspot virus (CymRSV) and a method for detecting CymMV, ORSV, and CymRSV, along with a method for their detection, are disclosed. The method involves designing multiplex real-time quantitative PCR detection primers and probes for CymMV, ORSV, and CymRSV and applying these primers and probes to the real-time quantitative PCR simultaneous detection of CymMV, ORSV, and CymRSV. It allows for faster detection of CymMV, ORSV, and CymRSV, taking only one-third of the time compared to uniplex real-time quantitative PCR technology, thereby reducing testing costs by approximately ? to ½ for each sample. The primers and probes are highly specific and sensitive, with a sensitivity as low as 1 to 10 copies. It provides an efficient and feasible detection method for early detection and prevention of CymMV, ORSV, and CymRSV.

Abstract: An electronic device having a display screen that displays a user interface including at least one object, comprising: a display mechanism that displays the user interface; a coordinate detection mechanism that detects coordinates of a user touch point on the display screen; a first feedback presentation mechanism that presents tactile feedback at a prescribed point to make the user perceive the presence of an object; a measurement mechanism that measures a force generated by the user pressing the display screen; and a second feedback presentation mechanism that detects an operation trigger based on the force and generates mechanical vibration.

Abstract: An electronic device having a display screen that displays a user interface including at least one object, comprising a display mechanism that displays the user interface; a coordinate detection mechanism that detects coordinates of a user touch point on the display screen; a first feedback presentation mechanism that presents tactile feedback at a prescribed point to make the user perceive the presence of an object; a measurement mechanism that measures a force generated by the user pressing the display screen; and a second feedback presentation mechanism that detects an operation trigger based on the force and generates mechanical vibration.

Abstract: An electronic device having a display screen that displays a user interface including at least one object, comprising: a display mechanism that displays the user interface; a coordinate detection mechanism that detects coordinates of a user touch point on the display screen; a first feedback presentation mechanism that presents tactile feedback at a prescribed point to make the user perceive the presence of an object; a measurement mechanism that measures a force generated by the user pressing the display screen; and a second feedback presentation mechanism that detects an operation trigger based on the force and generates mechanical vibration.

Abstract: An electronic device having a display screen that displays a user interface including at least one object, comprising a display mechanism that displays the user interface; a coordinate detection mechanism that detects coordinates of a user touch point on the display screen; a first feedback presentation mechanism that presents tactile feedback at a prescribed point to make the user perceive the presence of an object; a measurement mechanism that measures a force generated by the user pressing the display screen; and a second feedback presentation mechanism that detects an operation trigger based on the force and generates mechanical vibration.

Abstract: An electronic device having a display screen that displays a user interface including at least one object, comprising: a display mechanism that displays the user interface; a coordinate detection mechanism that detects coordinates of a user touch point on the display screen; a first feedback presentation mechanism that presents tactile feedback at a prescribed point to make the user perceive the presence of an object; a measurement mechanism that measures a force generated by the user pressing the display screen; and a second feedback presentation mechanism that detects an operation trigger based on the force and generates mechanical vibration.

Abstract: An electronic device having a display screen that displays a user interface including at least one object, comprising: a display mechanism that displays the user interface; a coordinate detection mechanism that detects coordinates of a user touch point on the display screen; a first feedback presentation mechanism that presents tactile feedback at a prescribed point to make the user perceive the presence of an object; a measurement mechanism that measures a force generated by the user pressing the display screen; and a second feedback presentation mechanism that detects an operation trigger based on the force and generates mechanical vibration.

Abstract: The present disclosure provides methods of identifying transplant rejection through the use of heparan sulfate as a biomarker. Method also comprise treating and/or preventing transplant rejection in a subject comprising administering to the subject a heparan sulfate inhibitor, thereby treating and/or preventing the development of immune-mediated injury following transplantation.

Abstract: A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or stimulating an immune response in a human to a viral-associated disease or cancer comprising administering to the human (i) the aforementioned human cell line in an amount sufficient to induce or stimulate an immune response to the viral associated disease or cancer, (ii) a human cell line, which lacks MHC-I and MHC-11 antigens and which has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficie

Abstract: The present disclosure provides methods of inhibiting an immune response to a viral vector used in gene therapy, such as adeno-associated virus (AAV), which involves co-administration of viral vector and an interfering molecule. The interfering molecule functions by either disrupting the TLR9-MyD88-type I IFN signaling pathway and/or neutralizing Type I IFNs, thereby inhibiting the immune response directed against the viral vector. The methods additionally encompass the step of re-administering the viral vector.

Abstract: A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or stimulating an immune response in a human to a viral-associated disease or cancer comprising administering to the human (i) the aforementioned human cell line in an amount sufficient to induce or stimulate an immune response to the viral associated disease or cancer, (ii) a human cell line, which lacks MHC-I and MHC-11 antigens and which has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficie

Abstract: A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or stimulating an immune response in a human to a viral-associated disease or cancer comprising administering to the human (i) the aforementioned human cell line in an amount sufficient to induce or stimulate an immune response to the viral associated disease or cancer, (ii) a human cell line, which lacks MHC-I and MHC-11 antigens and which has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficie

Abstract: A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or stimulating an immune response in a human to a viral-associated disease or cancer comprising administering to the human (i) the aforementioned human cell line in an amount sufficient to induce or stimulate an immune response to the viral associated disease or cancer, (ii) a human cell line, which lacks MHC-I and MHC-11 antigens and which has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficie

Abstract: A method of reducing immune response during gene therapy is provided which involves co-administration of the viral vector bearing a therapeutic transgene and a selected immune modulator capable of inhibiting the formation of neutralizing antibodies and/or CTL elimination of the vectors upon repeated administration.

Abstract: A method of reducing immune response during gene therapy is provided which involves co-administration of the viral vector bearing a therapeutic transgene and a selected immune modulator capable of inhibiting the formation of neutralizing antibodies and/or CTL elimination of the vectors upon repeated administration.

Abstract: A method of reducing immune response to a viral vector containing a selected transgene is provided. The method involves co-administration of the viral vector and a selected immune modulator capable of inhibiting the formation of neutralizing antibodies and/or CTL elimination of the vectors upon repeated administration.

Abstract: A method of reducing immune response to a viral vector containing a selected transgene is provided. The method involves co-administration of the viral vector and a selected immune modulator capable of inhibiting the formation of neutralizing antibodies and/or CTL elimination of the vectors upon repeated administration.

Abstract: A method of reducing an immune response to a recombinant adenovirus which involves co-administration of the recombinant adenovirus and a selected immune modulator. The immune modulator functions by inhibiting the formation of neutralizing antibodies and/or reducing CTL killing of the virally infected cells. The method additionally encompasses the step of re-administering the recombinant adenovirus.